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showed multiple pelvic masses, enlarged para-aortic lymph nodes, and
a liver hypodensity concerning for a neoplasm. The patient was trans-
ferred to a tertiary care center for further evaluation. Upon arrival,
serum tumor markers, HCG and AFP, were normal (CA-125 not done),
and she underwent a diagnostic laparoscopy which revealed bilaterally
enlarged ovaries with several 1–3 cm masses in the cul-de-sac that
were biopsied. Microscopy demonstrated islands of primitive small
round blue cells in a ﬁbroblastic stroma with abundant necrosis and
scattered calciﬁcations (Fig. 1). The tumor was mildly pleomorphic and
composed of small cells with hyperchromatic nuclei, irregular nuclear
contours and clear cytoplasm. Immunohistochemistry was strongly reac-
tive for desmin, pan-cytokeratin, NSE, CD56, and EMA, and showed focal
immunoreactivity for CD99, NB-84a, and bcl-2. The tumor cells were neg-Introduction
Desmoplastic small round cells tumor (DSRCT) is a rare intra-
abdominal neoplasm. It is primarily found in young men with a reported
male to female ratio of four to one (Ota et al., 2010). Common presenting
symptoms include abdominal pain and distension. Unfortunately, DSRCT
is oftenwidelydisseminated throughout theperitoneal cavity at diagnosis
and quickly recurs despite treatment so prognosis is exceedingly poor.
Given themale predominance of this disease, DSRCT rarely enters the
differential diagnosis in young womenwith an ovarianmass; however, it
is important to keep DSRCT inmind as it may inﬂuence how aggressively
one chooses to surgically treat a patientwith an unusual pelvicmass. This
study's objective was to provide an overview of this uncommon disease,
add three cases (including a 6-year-old girl) to the previously reported
12 and review the literature for treatment recommendations.Case reports
Case 1
A 6-year-old female presented to a local hospital with intractable
abdominal pain (previously diagnosed as constipation) that wasia.edu (J. Nakayama),
nc. Open access under CC BY-NC-SA licenseative for FLI-1, S-100, myogenin, and LCA. Cytogenetic testing showed an
Ewing sarcoma (EWS) gene disruption in the majority of her tumor cells
(Fig. 2). The morphology, immunohistochemistry and cytogenetic ﬁnd-
ings were all consistent with the diagnosis of DSRCT.
After surgery, further evaluation revealed bone marrow, liver,
and retroperitoneal lymph node involvement; additionally a PET scan
conﬁrmedmediastinal, peri-pancreatic,mesenteric, and retroperitoneal
spread. The patient's care was transferred to a regional center specializ-
ing in DSRCT where she received the P6 regimen: seven cycles of the
sarcoma chemotherapy regimen IE/VDC (Ifosfamide, Etoposide,
Vincristine, Adriamycin, and Cytoxan) chemotherapy. She progressed
in 3 months with leptomeningeal metastases. After 3600 cGy of
craniospinal radiation with a 540 cGy boost to the brain and TMZ-
CPT-11 for 12 cycles, she was disease free. However, the patient
recurred 11 months later and progressed through 4 months of cyclo-
phosphamide, vinorelbine, and bevacizumab. She was placed on a
phase I trial of IMC-A12 and temsirolimuswithout response. The patient
expired 28 months after her initial diagnosis.Case 2
A 28-year-old female presented with one month of abdominal pain
and pressure. CT showed multiple abdominopelvic masses, mesenteric
lymph nodes, and a peri-splenic mass. CA-125 was 42 U/mL. Biopsy
results were consistent with DSRCT, and she received 14 cycles of
neoadjuvant IE/VDC with the removal of adriamycin after the eighth
cycle due to cardiac toxicity. Following an incomplete response, the
patient underwent an exploratory laparotomy. Intra-operative ﬁndings
included a 10 × 8 cm right ovarian cystic mass, an 8 cm nodule. 
Fig. 1.Microscopic appearance of DSRCT: Islands of small round blue cells surrounded by
ﬁbroblastic stroma.
17J. Nakayama et al. / Gynecologic Oncology Reports 7 (2014) 16–18between the stomach and the spleen and small implants in the
cul-de-sac and omentum. A bilateral salpingo-oophorectomy, resection
of cul-de-sac peritoneum, and splenectomy, and omentectomy were
performed leaving her without visible disease. Microscopy showed
cords of small round blue cells. Immunohistochemistry revealed strong
and diffuse positivity for desmin and multifocal keratin positivity. CD99
was negative. Cytogenetics was negative for the EWS-WT1 translocation.
She returned on post-operative day 5 with a fascial dehiscence
which was repaired without complication. The patient ﬁnished the
last 2 cycles of her 16 cycle chemotherapy regimen and did well for
6 months. At that time, a CT showed increased abdominopelvic disease
and a bone scan was consistent with metastasis. She was started on
cytoxan/topotecan which she received from her local oncologist. The
patient expired of her disease 40 months after her initial diagnosis.Case 3
A 17-year-old female presented with several months of increased
abdominal girth associated with pelvic pain and nausea. Ultrasound
showed a 10 cm right adnexal mass and ascites. Serum tumor
markers were drawn and showed normal AFP, beta-HCG and LDH.
CA-125 was 35.9 U/mL, and her inhibin was elevated to 481 pg/mL.Fig. 2. Cytogenetic diagnosis of DSRCT: Fluorescent in situ hybridization for EWS
(Ewing's sarcoma) gene and WT1 gene disruption. Yellow corresponds to an intact
gene while red and green represent a disruption.She underwent an exploratory laparotomy which found a 15 cm
multicystic right ovarian mass with tumor implants on the left ovari-
an serosa, peritoneum, epiploica, liver, omentum and cul-de-sac. A
right salpingo-oophorectomy, peritoneal stripping of the anterior
cul-de-sac, appendectomy, and argon laser ablation of tumor nodules
were performed. The patient was optimally debulked but visible
sub-centimeter disease was present at the end of the procedure. Mi-
croscopy was consistent with DSRCT, and immunohistochemistry re-
vealed tumor diffusely positive for keratin, desmin, p63, and focally
positive for FLI-1. Stains were negative for S-100, WT-1, CD99, and
inhibin. The cytogenetic studieswere positive for the EWS-WT1 translo-
cation. The patient is now status post 9 cycles of IE/VDC chemotherapy
with interval debulking after seven cycles. She then received whole ab-
dominal radiation with a pelvic boost. She is alive without disease at
11 months from her diagnosis.
Discussion
DSRCT is a rare clinical entity with only 12 prior reported cases in
women in the English literature. Unfortunately, ovarian DSRCT pre-
sents early in life at an average age of 19 years and life expectancy
ranges from 4 to 42 months (see Table 1) (Ota et al., 2010; Young
et al., 1992; Zaloudek et al., 1995; Elhajj et al., 2002; Fang et al.,
2008; Engohan-Aloghe et al., 2009). Common symptoms at presenta-
tion are an abdominal mass, constipation, pain, nausea/vomiting and
weight loss (Fang et al., 2008; Church et al., 2006). CA-125 is often
elevated with a wide reported range (35.9–2823 U/mL). Generally,
only one ovary is involved with an average size of 11 cm, but most
patients have widespread disease throughout the peritoneal cavity
on presentation. The most common sites of metastasis are the liver,
lymph nodes, lung and bone marrow (Church et al., 2006).
Histologically, DSRCT is characterized by small round cells with
scanty cytoplasm in nests. The tumor cells are typically surrounded
by dense desmoplastic cytoplasm which is an important characteris-
tic suggesting the DSRCT diagnosis (Engohan-Aloghe et al., 2009).
However, making a deﬁnitive diagnosis based on morphological char-
acteristics alone is often not possible. The differential of small round
tumor cells includes Ewing's sarcoma, rhabdomyosarcoma, primitive
neuroectodermal tumor, lymphoma, adrenal neuroblastoma, and
hepatoblastoma (Elhajj et al., 2002). Immunohistochemistry and cy-
togenetics are used to conﬁrm the diagnosis. DSRCT has a characteris-
tic co-expression of epithelial (keratin, epithelial membrane antigen),
mesenchymal (vimentin, desmin), and neural antigens (neuron spe-
ciﬁc enolase) (Ordonez, 1998). Other stains which are often positive
are WT-1, FLI-1, and CD99 (Fang et al., 2008). Staining negative for
myogenin, MyoD1, chromogranin, HMB-45 and CD45 can also help
to distinguish DSRCT from other forms of small round cell tumors.
Additional conﬁrmation of the DSRCT diagnosis is made via detection
of the chromosomal translocation t(11;22)(p13;q12). This transloca-
tion fuses the Ewing sarcoma gene (EWS) with the Wilms' tumor
suppressor gene (WT1) to create a gene that likely acts as a tran-
scriptional activator for pro-tumorigenic genes (Fang et al., 2008).
However, the EWS-WT1 fusion is not always present (Ota et al.,
2010).
Given the rarity of ovarian DSRCT, there is no consensus on treat-
ment. Despite responding well to chemotherapy, tumors recur quick-
ly and long term survival is poor. In a study of 66 patients (91% male)
with general DSRCT, the overall 5-year survival rate was 15%. This
study also showed that patients who received primary debulking sur-
gery, multi-agent chemotherapy, and radiation had a signiﬁcantly im-
proved survival over those who did not receive all three modalities
(3-year survival: 55% versus 27% p b 0.02) (Lal et al., 2005). There
is also no gold standard chemotherapy regimen, but there is evi-
dence that a high dose alkylator-based regimen improves survival
(Kushner et al., 1996). The “P6 protocol,”which is four cycles of cyclo-
phosphamide, adriamycin and vincristine (VDC) with a cycle of
Table 1
Summary of the reported cases of ovarian DSRCT.
Case number Age
(years)
Ovarian involvement CA-125
(U/mL)
Cytogenetic
evidence
Initial treatment Follow-up
1 15 9 cm and 8.5 cm unknown
laterality. (masses solid)
Not done Not done Surgical debulking with multi-agent chemotherapy
including carboplatin
Died 4 months
2 15 Right: 15 cm (solid/cystic)
Left: 9 cm (solid)
Not done Not done Surgical debulking, no chemotherapy Secondary debulking
at 7 months
3 14 Right: 5.3 cm (solid) Not done Not done Surgical debulking None
4 22 Right: 8 cm (solid),
Left: 6.5 cm (solid)
125 Not done Surgical debulking, chemotherapy with BEP Died at 18 months
5 11 Right: 12 cm (solid/cystic) 88.5 Note done Surgical debulking, P6 and myeloablative chemotherapy Died at 11 months
6 23 Right: 6.8 cm (solid) 140 Not done Surgical debulking, platinum and taxol chemotherapy None
7 27 Right: 13 cm, Left: 20 cm Not done Not done Surgical debulking, delayed chemotherapy until
symptomatic. C/E then VDC
Died at 42 months
8 26 Bilateral (solid) 745.8 Negative Surgical debulking, P6 chemotherapy Died at 23 months
9 19 Bilateral (solid) 2823 Supports Surgical debulking, BEP Died at 11 months
10 (Fang et al., 2008) 13 Left: 10 cm Not done Inconclusive Surgical debulking, BEP, radiotherapy Died at 21 months
11 (Fang et al., 2008) 23 Right: 11 cm
Left: 9 cm
51.7 Surgical debulking, myeloablative chemotherapy Alive at 7 months
12 (Engohan-Aloghe
et al., 2009)
21 Right: 18 cm (solid)
Left: unclear (solid)
Not done Supports Surgical debulking, unknown chemotherapy Alive at 7 months
Case 1 6 Bilateral (solid) Not done Supports Surgical debulking, P6 chemotherapy Died at 28 months
Case 2 28 Right: 10 cm (solid/cystic) 42 Negative Neoadjuvant IE/VDC chemotherapy, debulking surgery Died at 40 months
Case 3 17 Right: 15 cm (multicystic) 35.9 Supports Surgical debulking, IE/VDC chemotherapy with interval
debulking followed by radiation therapy
Alive at 11 months
Summary of reported cases of ovarian DSRCT (modiﬁed from Ota et al., 2010) BEP: bleomycin, etoposide, and cisplatin; C/E: cisplatin, etoposide; VDC: vincristine, adriamycin, and
cyclophosphamide; I/E: ifosfamide, etoposide.
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seven cycles, is often used. Unfortunately, the efﬁcacy of the high
dose alkylator regimens comes with signiﬁcant toxicity requiring
support with transfusions and antibiotics (Kushner et al., 1996).
The three patients in our series have consistent presentations, re-
sponse to treatment and survival to that seen in previously reported
cases. Given the rarity of this clinical entity, ovarian DSRCT is unlikely
to be on the differential diagnosis for an adnexal mass, but one should
keep it in mind in young patients with peritoneal metastasis. Al-
thoughmaximal tumor debulking is preferred, its efﬁcacy in improv-
ing survival is not as clear in ovarian DSRCT as it is for epithelial
ovarian cancer and quality of life issues must be taken into account
when determining course of therapy (Church et al., 2006). Therefore,
foregoing radical surgery and the attendant morbidity may some-
times be a better option to avoid delaying initiation of chemothera-
py. Despite aggressive therapy, patients with ovarian DSRCT face a
poor prognosis which highlights the need for further research and
improved therapeutic options.Conﬂict of interest statement
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